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Abstract
In autosomal dominant osteopetrosis type 2 (ADO2) CLCN7 mutations cause impaired osteoclast 
function. Severe consequences include skeletal fragility despite high bone mass, osteomyelitis, 
osteonecrosis, bone marrow failure, and severe cranial nerve impingement. There is no effective 
medical treatment for ADO2.
We recruited subjects with ADO2 into a 14-week, open-label, pilot clinical trial of interferon 
gamma-1b. Doses were titrated based on tolerability and if fasting serum C-telopeptide (CTX) was 
<25% above baseline at week 8, targeting doses of 100 mcg/m2 three times a week. The primary 
outcomes were change from baseline in CTX and N-telopeptide/creatinine ratio (NTX/Cr) at week 
14. Secondary outcomes included changes in urine calcium/creatinine ratio, bone formation 
markers and tolerability.
Nine adults and 3 children were recruited. Severe manifestations of ADO2 included histories of 
fractures (100%), osteomyelitis (16.7%), vision loss (50%), and anemia (58.3%). Baseline CTX 
and NTX/Cr were generally low-normal. Procollagen type I N-terminal propeptide was elevated or 
in the upper-normal range in 11/12 (91.6%) subjects. Elevations of AST and LDH were common.
One subject withdrew due to rash. Five subjects achieved doses of 50 ug/m2 three days a week, 
while 6 reached the full dose of 100 ug/m2 three days a week. Only 3/11 (27.3%) completing 
subjects achieved the primary outcome of increasing CTX ≥25% above baseline at week 14. The 
mean change from baseline in CTX at week 14 was +2.2% (SD 43.2%, p=0.86). Likewise, there 
was no significant change in NTX/Cr (mean change −2.1%, p=0.81). Interferon gamma-1b was 
poorly tolerated. Most subjects had adverse events, and the Mental Health and Mental Component 
Scales of the SF-36v2 declined slightly (p<0.05).
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Over 14 weeks, interferon gamma-1b failed to significantly increase bone turnover markers in 
ADO2 and was poorly tolerated. Consequently, interferon gamma-1b is unlikely to be effective for 
decreasing bone mass in ADO2.
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Introduction:
Autosomal dominant osteopetrosis type 2 (ADO2), also known as Albers- Schönberg 
disease, is caused by heterozygous mutations in the CLCN7 gene(1,2). While most mutations 
are missense mutations, occasional mutations causing amino acid deletion, frameshifts, 
splicing defects or premature stop codons are described. CLCN7 mutations result in 
decreased osteoclast function, but osteoclast generation remains normal, and high numbers 
of osteoclasts are seen on bone histology(3). ADO2 has an incidence of about 5.5 per 
100,000 persons. Despite the dominant inheritance pattern, the penetrance is only 
approximately 66%, suggesting other genetic or environmental modifiers(2,4).
ADO2 is sometimes referred to as a “benign” osteopetrosis to distinguish it from severe life-
threatening (“malignant”) infantile recessive osteopetrosis. However, “benign” is an 
inappropriate designation, as ADO2 patients may still suffer severe and sometimes life-
threatening complications of their disease(4). These complications include fragility fractures, 
despite elevated bone mineral density, as well as bone marrow failure, severe vision loss or 
other cranial nerve impairment, osteonecrosis, and osteomyelitis. Patients also have high 
rates of complications after orthopedic surgeries(5).
In culture, osteoclasts from affected ADO2 patients resorb bone (or dentin) poorly compared 
to osteoclasts from healthy controls(6). However, osteoclasts from non-penetrant carriers of 
CLCN7 mutations demonstrate normal resorption. This suggests that an osteoclast specific 
defect determines whether a patient is affected or a carrier with mutations in this gene.
Efforts to treat osteopetrosis medically, have included attempts to increase osteoclast activity 
using very high doses of calcitriol(7–9) or interferon gamma-1b(10,11) to increase osteoclastic 
resorption. The response to calcitriol in case reports was limited, though some change in 
bone turnover markers were reported. In small studies, of mostly infantile recessive 
osteopetrosis, 18 months of treatment with interferon gamma-1b increased bone turnover 
markers, and decreased trabecular bone area and areal bone density(10,11). Interferon 
gamma-1b is FDA approved for management of recessive osteopetrosis, typically being used 
as a bridge to bone marrow transplant. However the effectiveness of these agents in ADO2 
has not been established.
Until recently, lack of a mouse model hindered attempts at developing therapies. We 
generated a “knock-in” mouse model of the G213R mutation in CLCN7, which is syntenic 
to the human G215R mutation identified in several ADO2 kindreds(2,3,12). While 
homozygous mice have severe osteopetrosis and die by 4 weeks of age, the heterozygous 
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mice survive, but have high areal bone mineral density (BMD), with high bone volume/total 
volume (BV/TV) on microCT, and increased numbers of poorly resorbing osteoclasts on 
bone histology. This mouse model was used to test both calcitriol and interferon gamma-1b 
effect in ADO2(13). Treating 6-week old ADO2 mice for 8 weeks with interferon gamma-1b 
increased the ratio of serum C-telopeptide (CTX) /Tartrate resistant acid phosphatase 5b 
(TRAP5b) (representing osteoclast function and number respectively) and decreased BV/TV, 
suggesting possible benefit for managing this disease(13).
We conducted a pilot clinical trial of interferon gamma-1b in humans with ADO2 to test the 




This was a single center, open-label, dose-escalation study evaluating the efficacy, as defined 
by biochemical markers of bone resorption, and safety profiles of interferon gamma-1b 
(ACTIMMUNE) in ADO2 subjects. The primary outcomes were defined as change in 
fasting serum C-telopeptide (CTX) and N-telopeptide/creatinine ratio (NTX/Cr) from 
baseline after 14 weeks of treatment. Secondary outcomes included changes in other 
biochemical markers and tolerability.
Subjects: Eligible subjects were patients age 3–65 years having clinical features of ADO2, 
including increased bone mass, and classic radiographic features (such as rugger jersey 
spine, “endo-bone” and Ehrlenmeyer flask deformities, etc.). Genetic confirmation was not 
required. Key exclusion criteria were serum calcium >10.6 mg/dL at initial screening; 
estimated glomerular filtration rate (eGFR) <35 mL/min/1.73m2; nephrocalcinosis of Grade 
3 or higher on screening ultrasound; history of hepatitis C, alcoholism, or intravenous drug 
abuse; presence of moderate or severe renal disease or liver disease at screening, or any 
unstable illness likely to influence successful completion or subject risk based on the 
discretion of the primary investigator. Subjects were recruited from 2016–2017.
Intervention: After screening, subjects entered a dose escalation protocol to minimize side 
effects and improve tolerance, starting with a low dose of interferon gamma-1b(14). Subjects 
were taught self administration via subcutaneous injection, dosing three days out of each 
week with at least two days separating each dose (for example, Monday, Wednesday, 
Friday). From Day 0 to 6, subjects received 15 μg/m2 three days a week; from Day 7 to 14, 
subjects received 30 μg/m2 SC three days a week; from day 15–56 subjects received 50 
μg/m2 SC three days a week. Titration was then based on fasting serum CTX at day 56 
(week 8). If CTX had increased by ≥25% above the mean of the screening and baseline visit 
values, the interferon gamma-1b dose remained at 50 μg/m2 three days a week through week 
14. If CTX was <25% above the mean of screening and baseline visit values, then the 
interferon gamma-1b dose was increased to 100 μg/m2 three days a week through week 14. 
The target doses were based on the approved dose of interferon gamma-1b for severe 
recessive osteopetrosis and the animal studies(13). Doses were decreased on a case by case 
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basis to manage subsequent drug-related adverse events. Study drug was stopped at the week 
14 visit, and subjects attended a final followup visit 4 weeks after ceasing study drug.
Role of the sponsor: Interferon gamma-1b (ACTIMMUNE) and funding for the trial 
were provided by Horizon Pharmaceuticals. The study and analysis were conducted 
independently by the investigators.
Human subjects approvals.—This study was conducted in accordance with the 
Declaration of Helsinki and was approved by the Indiana University Institutional Review 
Board. Prior to enrollment, all subjects provided written consent after appropriate discussion 
of risks and benefits of participation. Children over age 7 provided written assent in 
accordance with local IRB procedures. The trial was listed on ClinicalTrials.gov identifier 
NCT02584608.
Assessments.—All laboratory specimens were collected in the fasting state for blood and 
urine. Primary efficacy and safety laboratories were measured at Covance Inc., Analytical 
Services Central Laboratory (Indianapolis, Indiana). Serum CTX was measured using the 
Beta-Cross-Laps assay (Elecsys electrochemiluminescence immunoassay, Roche 
Diagnostic). Additional assays included urine NTX ELISA (Osteomark, Ostex International 
Inc., Seattle, Wa); procollagen type I N-terminal propeptide (P1NP; 
Electrochemiluminescent immunoassay, Roche Diagnostic), Trap5b ELISA (Quidel, San 
Diego, Ca), 1,25-dihydroxyvitamin D was measured by LC-MS/MS (AB Sciex QTRAP 
5500), and bone specific alkaline phosphatase (Ostase EIA; Immunodiagnosticsystems, 
Gaithersburg, MD). Biochemistries were measured using standard clinical analyzers (Roche 
Cobas 8000, Indianapolis, IN). Complete blood counts with differential were assessed on 
standard clinical platforms. Samples were analyzed sequentially as the samples were 
collected, since treatment decisions were determined by values at certain time points 
(specifically CTX, and safety laboratory tests). As a secondary quality check, at the end of 
the study, samples from each subject were analyzed concurrently on the same assay in the 
investigator’s laboratory using an ELISA for serum CTX (Immunodiagnosticsystems Serum 
CrossLaps (CTX-I) ELISA, Gaithersburg, MD) and EIA for serum NTX ((Alere 
Scarborough, Inc. OSTEOMARK NTx Serum (EIA) Scarborough, ME). Presense of 
interfering anti-Interferon gamma-1b antibodies were assessed in serum using ELISA by 
Intertek (Manchester, UK). Bone density of the lumbar spine (L1-L4) was measured at 
baseline using dual energy x-ray absorptiometry (DXA) using the GE Lunar Prodigy 
Advance (Madison, WI, USA) and Z-scores were calculated using age and sex normative 
data. The planned 14 week duration of treatment was considered too short to be likely to 
detect changes in bone density; thus, serial densitometry was not performed.
Patient reported outcomes were collected using SF-36v2 at baseline and at week 14. The 
SF-36v2 includes 36 questions addressing 8 concepts for health related quality of life: 
Physical Functioning, Role Limitations due to Physical Health, Bodily Pain, General Health 
Perceptions, Vitality, Social Functioning, Role Limitations due to Emotional Problems, and 
Mental Health. Normative based standardized scores are calculated. Scores less than 50 are 
considered below the mean for the US population (mean is 50 and SD 10). Concepts are also 
grouped into a Physical Component Score and a Mental Component Score.
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Statistics.—Descriptive statistics were calculated for all variables and reported as means 
(standard deviations) or median (minimum, maximum) values for continous variables and 
frequencies (percentages) for categorical variables. Percent changes in bone markers (CTX 
and NTX/Cr) from baseline were summarized as means and standard deviations and tested 
for significance using Student’s t-test. Median change for CTX was also evaluated using 
Wilcoxon rank sum test. Longitudinal changes in measured variables were evaluated using a 
linear mixed effect model with time as a categorical variable. Additionally, the proportions 
of subjects obtaining changes in bone markers ≥25% from baseline were estimated with 
their 95% Agresti-Coull confidence intervals. CTX and NTX/Cr measurements during dose 
escalation, at peak dose, and at study end were analyzed by repeated measure analysis of 
variance to evaluate dose response and to determine whether bone resorption markers are 
stable once final dose therapy is achieved. Paired T-tests were used to compare the results of 
SF36-v2 domain results from baseline and week 14.
Power was calculated for a planned enrollment of 12 subjects in this pilot study, providing a 
power of 80% at a p value of 0.05 to detect change in serum CTX ≥25% from baseline with 
a standard deviation of 28.1% using Student’s t-test. With the 11 subjects that completed the 
full protocol, the resulting power was 76%. Endpoints were assessed on all subjects 




All 12 of the subjects screened were enrolled, and 11 subjects completed the full protocol. 
Baseline clinical characteristics are shown in Table 1. Three subjects were children (ages 
8.1, 9.6 and 15.9 years). All subjects had classic radiographic characteristics consistent with 
the diagnosis of ADO2. Lumbar spine Z-scores, as measured by DXA, ranged from +4.7 to 
+15.5. Patients were mostly from families with confirmed mutations in CLCN7; 4 subjects 
were from families with G215R, and 6 subjects were from families with R286W. Genotype 
was not available for 2 adult subjects, one of whom had an affected daughter consistent with 
dominant inheritance, while the other subject had no affected relatives.
As a group, the enrolled subjects had severe manifestations of ADO2 including histories of 
fractures (100%), multiple fractures (91.7%), osteomyelitis (16.7%), vision loss attributable 
to ADO2 (50%), and anemia (58.3%). Two children had a history of intracranial 
decompression surgeries of the optic nerve canal to attempt to preserve vision. Three 
patients were legally blind in one or both eyes. One child and one adult were transfusion 
dependent due to anemia. Two subjects had fractured during the 2 years prior to baseline, 
and 2 subjects fractured during the trial. The clinical features and disease severity of the 
three children were similar to those of the adults. Patients were not taking calcitriol during 
the trial, though 4 (33.3%) subjects had previously attempted treatment with calcitriol, all > 
6 years prior to enrollment.
Baseline laboratory values are shown in Table 2 (with reference ranges in Supplemental 
Table S1). All subjects had normal serum calcium, phosphorus and total alkaline 
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phosphatase for age. Blood urea nitrogen and serum creatinine were normal. Two subjects 
(16.7%) had elevated 1,25-dihydroxyvitamin D concentrations, including the one subject 
with elevated PTH. Urine calcium/creatinine ratio was <0.2 mg/mg in all subjects, and < 0.1 
mg/mg in 10 (83%).
Baseline Bone turnover markers: CTX was normal for age in all subjects. Urine NTX/
creatinine ratio was normal, except for one subject with a low value. However, most subjects 
were in the lower end of the age appropriate normal range for one or both tests. TRAP5b 
was elevated for age in all subjects. Total alkaline phosphatase was normal for age. Bone 
specific alkaline phosphatase was low for age in two pediatric subjects (ages 8.1 and 15.9 
years), but normal in the rest of the subjects. However, for most subjects P1NP was either 
above normal (7/12 or 58.3%) or near the upper end of the normal range (4/12 or 33.3%). 
Consistent with the normal age appropriate differences in bone turnover markers, the 
children had higher bone formation and resorption markers than the adults.
Mild elevations of AST were present in 8 (75%) subjects, including all three children, but 
only one subject had mild elevation of ALT. The two youngest subjects (both boys) had 
slight elevations in GGT. LDH was above normal in 10/12 (83%) subjects. Total creatine 
kinase was elevated for age in 7/12 (58.3%) subjects.
Blood cell counts provided evidence indicating bone marrow impairment in studied subjects. 
Seven (58.3%) were anemic, including one who had received a recent transfusion prior to 
screening. Four (33.3%) subjects had low white blood cell counts, and 3 (25%) were 
neutropenic. Two (16.7%) subjects had platelet counts less than 100 ×103/ uL. No subjects 
had immature neutrophils (bands) or elevated neutrophil counts detected at baseline. 
Hepatomegaly or splenomegaly was not noted on physical examination during the study in 
any patients.
Response to treatment.
At week 8, 4 subjects (33.3%) had increased serum CTx ≥25% from baseline, and continued 
on 50 ug/m2 three days a week according to protocol. Due to tolerability of symptoms, an 
additional subject remained at 50 ug/m2 instead of dose escalating at week 8. One subject 
discontinued the study drug after 6 weeks due to a rash, while taking 50 ug/m2 three days a 
week. Thus, six subjects achieved the full dose of 100 ug/m2 (three days a week), while 6 
subjects only achieved a dose of 50 ug/m2. No subject decreased their dose from the highest 
dose achieved.
Individual subject plots of serum CTX and urine NTX/creatinine ratio are shown in Figure 1. 
The percent changes in serum CTX, urine NTX/creatinine ratio and urine calcium/creatinine 
ratio are shown in Figure 2. At week 14, only 3/12 (25%) of the subjects achieved the 
primary outcome of CTX ≥25% above baseline, though 50% of subjects increased CTX 
≥25% at some point in the study, without sustained increases. The mean change in serum 
CTX at week 14 was only +2.2% (SD 43.2%, p=0.86), while the median change was 
actually a decrease (−14.5%, p=0.85 by Wilcoxon rank sum test). Table 3 shows the percent 
change in serum CTX and urine NTX/creatinine ratio by study visit. Supplemental Table S2 
shows the proportions of subjects at each time point with increases ≥25% bone resorption 
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marker changes from baseline. The 3 subjects that had CTX ≥25% above baseline at week 
14 were adults, one with G215R, one with R286W and one whose genotype was not tested. 
Two were receiving 50 mcg/m2, while one was receiving 100 mcg/m2. There were not 
differences between these 3 subjects and the other subjects for assessed variables.
Similarly, the mean change in urine NTX/creatinine ratio at week 14 was not significant 
[−2.1% ( SD 29.1%), p=0.81]. At week 14 only 17% had urine NTX/creatinine ratio ≥25% 
above baseline. Although 58% of subjects had an increase in urine NTX/creatinine ratio 
≥25% above baseline at some point in the trial, there were not consistent increases. Trap5b 
and CTX/Trap5b ratio also did not change significantly during the course of treatment.
In a mixed effects model using time as a categorical variable, changes in bone resorption 
markers remained nonsignificant. There was not a significant dose or time relationship.There 
was considerable variability among subjects. Some subjects had increases in one resorption 
marker and decreases in the other. Notably the subject with the largest percent increase in 
serum CTX, also had a decrease in urine NTX/creatinine ratio.
In general similar proportions of subjects had decreases in serum CTX ≥25% (7/12, 58%) as 
had increases ≥25% (6/12, 50%) at some point during treatment. Likewise, similar 
proportions of subjects had decreases in urine NTX/creatinine ≥25% (5/12, 42%) as had 
increases ≥25% (7/12, 58%) at any point.
To ensure that a potential therapeutic effect on bone resorption markers was not missed by 
having samples run on separate days at the central laboratory, we also measured serum CTX 
and serum NTX on stored samples, batching all of an individual subject’s samples on the 
same assay kit. These assays confirmed no significant change from baseline in serum CTX 
(p=0.84) or serum NTX (p=0.65).
Serum calcium was unchanged during the study. Fasting urine calcium/creatinine ratio was 
assessed on therapy as a potential marker of calcium resorption from bone. There was no 
significant increase in urine calcium/creatinine ratio over time using mixed effect models 
(p=0.78). Urine calcium/creatinine ratio increased to 0.25 mg/mg in one subject at week 4 
and another at week 14. There were no occurrences of symptomatic kidney stones during the 
trial. There were also not significant changes in other mineral metabolism parameters during 
the trial, including P1NP, BSAP, serum phosphorus, or PTH. Interfering antibodies to 
interferon gamma-1b were not detected in any subject.
SF36 results.
We assessed patient reported QOL using the SF36v2 short form (Table 4). Except for the 
Mental Health score, at baseline all subscale mean scores were below the US population 
mean, though all were within 1SD. The Physical Component Scale score was also below the 
US population mean, though the Mental Component Scale score was not. When assessed at 
week 14, the Mental Health Scale and Mental Component Scale declined significantly from 
baseline, but remained similar to US norms. All other scales did not significantly change 
during treatment.
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All subjects (100%) had one or more treatment emergent adverse events. Most adverse 
events were mild or moderate in severity. The most common treatment emergent adverse 
events were headache (83%), fatigue (75%), nausea (75%), flu-like symptoms (67%), 
myalgia (58%), decreased white blood cell count (50%), arthralgia (42%), diarrhea (42%), 
vomiting (42%), back pain (33%), injection site reaction (33%), and pain in extremities 
(33%). One subject discontinued the protocol after 6 weeks due to urticarial rash. The 
median (minimum, maximum) number of moderate or severe adverse events was 6 (1, 27) 
among patients that had decreases in mental health scores, and 5 (2, 8) among subjects that 
did not have decreases in mental health scores.
No subject developed an elevated neutrophil count. White blood cell count and absolute 
neutrophil count decreased during the trial with a nadir at week 11, but the decreases over 
time were not statistically significant. However two subject developed anemia (17%), five 
had decrease in neutrophil count (42%), and three had decreased platelet count (25%). Two 
subjects developed severely low neutrophil count (defined as <1.0 ×103/ uL; one subject 
with 0.58 ×103/ uL and another with 0.83 ×103/ uL), which recovered. There was no 
evidence during the study of increased immature neutrophils. One subject had detectable 
bands of 0.02 ×103/ uL (1% of their total white blood cells) at 4 weeks, and another subject 
had 0.05 × 103/ul (2% of their total white blood cells) at 14 weeks, which were near the 
lower end of the normal range (0 – 0.27 × 103/ul, or 0–3% of total white blood cells). No 
other subjects had measurable bands during the study. Three subjects had 2 infections each 
during the course of treatment. There were no serious adverse events.
Discussion
In this open label clinical trial, fourteen weeks of treatment with interferon gamma-1b, failed 
to significantly and consistently increase biochemical markers of bone resorption in patients 
with severe clinical manifestations of ADO2. There was no dose or time relationship to the 
pattern of bone resorption markers. To our knowledge this is the largest trial to evaluate the 
effects of interferon gamma-1b in a cohort of patients with ADO2.
Interferon gamma-1b was used to increase bone resorption in small trials of patients with 
osteopetrosis(10,11). Although not genetically defined, most of the subjects in those trials 
were young children and likely had recessive forms of osteopetrosis, though two adults were 
included that may have had dominant osteopetrosis(10,11). The authors reported increases in 
urinary hydroxyproline, NTX and urine calcium by 6 and 18 months of therapy. On bone 
biopsy, they found a corresponding decrease in trabecular bone area, despite no change in 
osteoclast number. Six of those patients had bone mineral density testing which indicated 
decreases in lumbar spine BMD(11). Inteferon gamma-1b is FDA approved for management 
of recessive osteopetrosis, often being used as a bridge to bone marrow transplant(11).
Our group recently generated a mouse model of ADO2 due to mutations in CLCN7, which 
enabled testing of therapies for ADO2. After 8 weeks of low (1.5 ug/kg three times a week), 
medium (7.5 ug/kg three times a week), or high (37.5 ug/kg three times a week), doses of 
Interferon gamma-1b young (6 week old) ADO2 mice demonstrated improvements in 
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osteoclast resorption markers, and in BV/TV(13). Areal BMD and BMC measured by DXA 
were attenuated and micro-CT measurements indicated reduced BV/TV and trabecular 
thickness. The low doses used in this animal study were still somewhat higher than doses 
tolerated by humans, while the medium and high doses were several times higher than that 
used in humans. Based on the skeletal improvements even at the lower dose level mice, we 
anticipated positive results in this human trial.
In the current pilot trial patients with ADO2, all had severe manifestations of their disease, 
including evidence of bone marrow impairments, or frank marrow failure. The reason for 
lack of increased resorption markers could include reduced sensitivity of osteoclasts to the 
effect of interferon gamma-1b compared to mice, different genotypes compared to the prior 
study of mostly recessive osteopetrosis, or insufficient duration of treatment. Prior studies in 
primarily recessive osteopetrosis did not report bone turnover markers at earlier time points 
than 6 or 18 months for comparison(10,11). Administering interferon gamma-1b to human 
granulocyte-macrophage cultures from osteopetrotic patients results in measurable 
differences in cell activity reported from interferon gamma-1b within 5 days(15). The 
assumption in the design of this trial was that effects on osteoclastic bone resorption would 
be detectable using bone resorption markers before changes in bone density would be 
measurable.
Perhaps the doses acheivable were not high enough to have similar effect in humans as in the 
mouse model. However, our doses were consistent with doses used in other human diseases, 
and were at the limit of general tolerability regarding side effects. Most patients had 
significant drug-related symptoms repeatedly with dosing. We used a higher maximum dose 
(100 mcg/m2) than those earlier osteopetrosis trials (50 mcg/m2) and measured multiple 
bone turnover markers, but still did not demonstrate increased bone resorption. Another 
possibility is that we did not identify the most optimal biomarker for early effect of 
interferon gamma-1b. However, osteoclastic activity would be necessary to increase bone 
resorption, and hopefully improve bone quality as well as increase marrow space. Thus 
resorptive markers would be expected to increase if having an effect to decrease bone mass. 
Of note, we also saw no significant changes in any measured bone formation marker. 
Notably, in a case report of severe recessive osteoporosis, interferon gamma-1b treatment for 
17 weeks also failed to increase urine calcium excretion or urine hydroxyproline, leading to 
discontinuation(8).
This study highlights some additional features of ADO2. We confirmed prior report of 
elevations in Trap5b and creatine kinase(16), and also in AST and LDH among ADO2 
patients(17). We also noted general baseline elevations in the bone formation marker P1NP, 
which were not previously described. Notably elevated P1NP was not recapitulated in the 
mouse model. Serum calcium, phosphorus, alkaline phosphatase and P1NP concentrations 
were similar in the WT and ADO2 mice bred to several different mouse strains, though 
TRAP was higher and CTX/TRAP ratio was lower in the ADO2 mice(12). Similar or higher 
P1NP levels in the setting of impaired osteoclast activity, suggests an uncoupling of bone 
formation and resorption, allowing the continued production of bone, even while failing to 
resorb and remodel appropriately. This may explain a lack of apparent growth impairment, 
and the normal sized, though abnormally shaped, bones in ADO2. One possible explanation 
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is that osteoblasts may still receive various signals in support of bone formation from the 
excessive numbers of poorly resorbing osteoclasts present in patients with CLCN7 
mutations. Similarly other models of impaired osteclast activity with preserved osteoclast 
numbers such as Cathepsin K knockout or inhibition, also demonstrate preservation of bone 
formation(18,19).
We also noted 2 subjects with elevated 1,25-dihyroxyvitamin D level. This has been 
previously reported in various osteopetrotic models(20,21), and in some osteopetrotic 
children. 1,25-dihydroxyvitamin D stimulates osteoclast activity, and increases osteoclast 
number in some recessive osteopetrotic models, though some studies have also suggested 
resistance of osteopetrotic osteoclasts to 1,25-dihydroxyvitamin D(21,22). The use of 
calcitriol (1,25-dihyroxyvitamin D) has been attempted in humans with osteopetrosis, but 
published data of successful management is limited in recessive osteopetrosis, and frankly 
lacking in ADO2. In fact, ADO2 mice treated with high dose calcitriol actually increased 
areal BMD and BV/TV(13), suggesting that this approach is likely to harm patients 
skeletally, in additions to the risks of associated hypercalciuria. Because of these mouse 
findings, we have abandoned the practice of treating ADO2 patients with calcitriol.
We also highlight the severe nature of ADO2, which has erroneously been refered to in the 
past as a “benign” disorder. Most of our patients had evidence of marrow failure and 
fractures, and half had various degrees of vision impairment related to ADO2.
This is the first study to our knowledge to assess patient reported quality of life outcomes in 
ADO2. Although subjects had quality of life scores on the SF-36v2 within 1SD of the US 
population mean, the Mental Health Scale and Mental Component Scales decreased 
significantly during the course of treatment. Declines in mental health quality of life may be 
due to the symptoms caused by administering interferon gamma-1b, or their perception of 
their overall disease burden. Patients having decreases in the mental health scores from 
baseline generally had more adverse events that were moderate or severe than those without 
decreases in mental health scores.
Strengths of our study include robust attempts to confirm effects on bone resorption 
biomarkers, which are generally expected to reflect substantial changes in bone turnover, 
even though smaller changes might not be detected. Despite significant symptoms, most 
patients completed the protocol, emphasizing the motivation of these patients to find a better 
treatment. Limitations include that due to the short duration of the study, indices of bone 
biopsy, or bone density were not assessed. Had a bone resorption signal been identified, we 
would have extended the trial to a duration sufficient to assess bone density changes. While 
our study could have missed a longer term effect on osteoclast resorption, given the poor 
tolerability and frequent systemic symptoms induced by interferon gamma, a longer 
treatment course was not considered warranted, without evidence for short term alteration in 
bone resorption markers.
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Interferon gamma-1b failed to significantly increase markers of bone resorption in this 14 
week trial in ADO2. Thus a long term effect on bone mass is not anticipated. Given the 
significant side effects with low tolerability experienced by the subjects, and the current lack 
of any preliminary indicator of benefit, treatment with interferon gamma-1b should not be 
pursued in ADO2. There is a need for novel, effective therapies for this condition.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Bone resorption markers during treatment with Interferon gamma-1b: serum CTX and urine 
NTX/creatinine ratio. Children are marked in dashed black lines and adults in solid gray 
lines.
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Percentage changes from baseline in serum CTX, urine NTX/creatinine ratio and fasting 
urine calcium/creatinine ratio. Some data of percent change in urine Ca/Cr for pediatric 
subject 007 were deleted from the overall plot due to extreme outliers (from a very low 
baseline value 0.011mg/mg, he had percent increases of +1049.26 at week11 and +2093.91 
at week14, but his highest Urine Ca/Cr was only 0.24 mg/mg). However there were no 
occurrences of hypercalciuria.
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Table 3.
Change in bone resorption markers.
Week N Mean SD Median Min Max P value
Percent change CTX (%) 0.8611
0 12 0.0 0.0 0.0 0.0 0.0
2 12 2.9 47.2 −5.4 −35.9 138.1
4 12 −0.8 33.6 −1.1 −50.0 81.0
8 11 13.2 44.8 10.0 −38.5 119.0
11 11 1.8 38.0 −11.3 −47.5 85.7
14 12 2.2 43.2 −14.5 −35.7 90.5
18 12 10.0 49.4 −4.5 −37.0 133.3
Percent change NTX/creatinine (%) 0.8081
0 12 0.0 0.0 0.0 0.0 0.0
2 12 −4.6 23.1 −1.3 −54.8 25.7
4 12 1.6 23.6 −9.4 −23.3 46.5
8 11 0.6 31.4 1.5 −48.8 49.8
11 11 4.2 28.5 1.7 −49.0 46.6
14 12 −2.1 29.1 −4.5 −50.5 55.5
18 12 3.2 34.3 −0.2 −48.6 56.7
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Table 4.
Summary of normalized SF36 Scales and comparison between baseline and week 14. US norms have mean 
50, SD 10. P values are for change from baseline; * p< 0.05.
Scale Week Mean SD Median Min Max 25th percentile 75th Percentile p-value from 
Paired t-test
Physical Functioning Scale 0 43.3 12.9 41.8 23.8 57.7 33.8 56.7 0.6912
14 41.8 14.3 37.8 19.8 57.7 30.8 57.7
Role Physical Scale 0 45.6 12.6 52.5 26.9 57.1 32.0 57.1 0.3802
14 42.4 13.4 44.4 22.3 57.1 31.6 54.8
Bodily Pain Scale 0 40.7 8.2 40.1 25.3 55.7 34.3 46.7 0.7334
14 41.4 12.1 38.0 21.2 62.3 32.1 51.2
General Health Scale 0 45.4 12.5 48.6 26.5 62.6 32.4 56.8 0.1126
14 43.6 13.6 43.9 26.5 62.6 30.1 56.8
Vitality Scale 0 47.8 9.8 48.8 33.7 70.0 39.7 51.8 0.2742
14 44.2 14.8 41.2 27.6 70.0 30.6 53.3
Social Functioning Scale 0 47.6 12.8 54.2 19.9 56.9 38.4 56.9 0.0584
14 41.0 14.9 46.3 14.6 56.9 27.8 54.2
Role Emotional Scale 0 49.6 10.0 56.1 33.9 56.1 39.4 56.1 0.1123
14 44.4 15.0 54.3 11.7 56.1 33.9 56.1
Mental Health Scale 0 52.6 9.8 55.3 36.3 63.5 45.8 60.8 0.0256*
14 47.4 11.9 48.5 28.1 63.5 37.6 58.0
Health Transition Item 0 2.9 1.2 3.0 1.0 5.0 2.5 3.5 0.7227
14 3.0 1.0 3.0 2.0 5.0 2.0 3.5
Physical Component Scale 0 40.9 10.6 38.3 27.0 56.6 32.0 50.6 0.9414
14 41.1 13.0 36.0 24.5 57.7 29.7 55.2
Mental Component Scale 0 53.0 12.3 58.3 32.9 66.5 39.4 62.9 0.0403*
14 46.3 13.9 49.2 20.1 64.7 37.2 57.1
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